Europäisches Patentamt
European Patent Office
Office européen des brevets

SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 21 75 12 84

Classification of the application (IPC):
C07K 14/71, ***A61K 38/00***, ***A61P 11/00***, ***A61P 13/12***, ***A61P 19/08***, ***A61P 21/06***, ***A61P 7/06***, ***A61P 9/12***

Technical fields searched (IPC):
C07K

DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
X	WO 2018067874 A1 (ACCELERON PHARMA INC [US]) 12 April 2018 (2018-04-12) * the whole document *	1-20

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search	Date of completion of the search	Examiner
The Hague	30 August 2024	Surdej, Patrick

CATEGORY OF CITED DOCUMENTS

X: particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A: technological background
O: non-written disclosure
P: intermediate document
T: theory or principle underlying the invention
E: earlier patent document, but published on, or after the filing date
D: document cited in the application
L: document cited for other reasons
& : member of the same patent family, corresponding document

EP 4 100 431 A4

Europäisches Patentamt
European Patent Office
Office européen des brevets

SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 21 75 12 84

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 1-4, 6-20(all partially)
A polypeptide comprising a variant ActRIIB amino acid sequence that is at least 90% identical to an amino acid sequence that begins at any one of amino acids 20-29 (amino acid residues 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) of SEQ ID NO: 2 and ends at any one of amino acids 109-134 (amino acid residues 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, or 134) of SEQ ID NO: 2, and wherein the variant ActRIIB amino acid sequence comprises the amino acid substitution at a position A24 of SEQ ID NO: 2

2. claims: 1-4, 6-20(all partially)
A polypeptide comprising a variant ActRIIB amino acid sequence that is at least 90% identical to an amino acid sequence that begins at any one of amino acids 20-29 (amino acid residues 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) of SEQ ID NO: 2 and ends at any one of amino acids 109-134 (amino acid residues 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, or 134) of SEQ ID NO: 2, and wherein the variant ActRIIB amino acid sequence comprises one or more amino acid substitutions at a position of SEQ ID NO: 2 selected from the group consisting of, respectively: S26, N35, E37, L38, R40, S44, L46, E50, E52, Q53, D54, K55, R56, L57, Y60, R64, N65, S67, G68, K74, W78, L79, D80

3. claims: 5(completely); 1-4, 6-20(all partially)
A polypeptide comprising a variant ActRIIB amino acid sequence that is at least 90% identical to an amino acid sequence that begins at any one of amino acids 20-29 (amino acid residues 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) of SEQ ID NO: 2 and ends at any one of amino acids 109-134 (amino acid residues 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, or 134) of SEQ ID NO: 2, and wherein the variant ActRIIB amino acid sequence comprises the amino acid substitution at a position F82 of SEQ ID NO: 2

4. claims: 1-4, 6-20(all partially)
A polypeptide comprising a variant ActRIIB amino acid sequence that is at least 90% identical to an amino acid sequence that begins at any one of amino acids 20-29 (amino acid residues 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) of SEQ ID NO: 2 and ends at any one of amino acids 109-134 (amino acid residues 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, or 134) of SEQ ID NO: 2, and wherein the variant ActRIIB amino acid sequence comprises one or more amino acid substitutions at a position of SEQ ID NO: 2 selected from the group consisting of, respectively: N83, T93, E94, Q98, V99, E105, E106, F108, E111, R112, A119, G120, E123, P129, P130, and A132

Only part of the further search fees have been paid within the fixed time limit. The present (supplementary) European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims: 5(completely); 1-4, 6-20(partially)

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search	Date of completion of the search	Examiner
The Hague	30 August 2024	Surdej, Patrick

CATEGORY OF CITED DOCUMENTS

X: particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A: technological background
O: non-written disclosure
P: intermediate document
T: theory or principle underlying the invention
E: earlier patent document, but published on, or after the filing date
D: document cited in the application
L: document cited for other reasons

& : member of the same patent family, corresponding document

EP 4 100 431 A4

Europäisches Patentamt
European Patent Office
Office européen des brevets

ANNEX TO SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 21 75 12 84

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on 30-08-2024
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2018067874 A1	12-04-2018	AU 2017338916 A1	18-04-2019
		AU 2022201698 A1	07-04-2022
		AU 2024200684 A1	22-02-2024
		BR 112019006918 A2	25-06-2019
		CA 3039525 A1	12-04-2018
		CN 110036025 A	19-07-2019
		EP 3523328 A1	14-08-2019
		JP 7280182 B2	23-05-2023
		JP 2019536440 A	19-12-2019
		JP 2023033573 A	10-03-2023
		KR 20190073414 A	26-06-2019
		KR 20230152811 A	03-11-2023
		MA 46471 A	19-05-2021
		US 2020055919 A1	20-02-2020
		US 2022306724 A1	29-09-2022
		WO 2018067874 A1	12-04-2018

EP 4 100 431 A4